Differences between oral cancer and cancers of the pharynx and larynx on a molecular level

Shiga,Kiyoto; Ogawa,Takenori; Katagiri,Katsunori; Yoshida,Fumiaki; Tateda,Masaru; Matsuura,Kazuto; Kobayashi,Toshimitsu

doi:10.3892/ol.2011.451

Differences between oral cancer and cancers of the pharynx and larynx on a molecular level

Authors:
- Kiyoto Shiga
- Takenori Ogawa
- Katsunori Katagiri
- Fumiaki Yoshida
- Masaru Tateda
- Kazuto Matsuura
- Toshimitsu Kobayashi
View Affiliations

Affiliations: Department of Otolaryngology-Head and Neck Surgery, Iwate Medical University Hospital, Iwate 020-8505, Japan, Department of Otolaryngology-Head and Neck Surgery, Tohoku University Hospital, Sendai, Miyagi, Japan, Department of Head and Neck Surgery, Miyagi Cancer Center Hospital, Natori, Miyagi, Japan
Published online on: October 19, 2011 https://doi.org/10.3892/ol.2011.451
Pages: 238-243

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to elucidate differences between oral cancers and cancers of the pharynx and larynx, we investigated the genetic and epigenetic changes in these tumors using molecular biology methods. Methylation of the promoter region of the p16 tumor suppressor gene was examined using methylation‑specific polymerase chain reaction in specimens from 47 oral, 39 pharyngeal and 35 laryngeal squamous cell carcinomas. These specimens were also characterized for allelic loss of certain areas of the genome, i.e., 3p22, 9p21 and 17p13 (TP53). The frequency of methylation of the promoter region of the p16 gene in tongue cancers (35.3%) was significantly higher than in pharyngeal (12.8%) and laryngeal cancers (11.4%) (p=0.046 and p=0.039, respectively). The frequency of methylation in tumors of female patients (47.1%) was significantly higher compared to tumors of male patients (15.4%) (p=0.0067). In contrast, the frequency of the loss of heterozygosity (LOH) at 3p21 in pharyngeal cancers (66.7%) was significantly higher than in oral cancers (20.0%) (p=0.0006). The frequencies of LOH at 17p13 in pharyngeal (71.0%) and laryngeal cancers (73.1%) were also significantly higher than in oral cancers (36.1%) (p=0.009 and p=0.009, respectively). Our results indicate that there are marked differences in the frequencies of the hypermethylation of genes and allelic loss between oral cancers and cancer of the pharynx and larynx. Although all of these tumors were diagnosed as squamous cell carcinomas, the process of carcinogenesis may be different in tumors located in various parts of the head and neck. Loss of function of tumor suppressor genes by allelic loss gives rise to tumors in the pharynx and larynx, while loss of function due to methylation of the promoter regions of those genes is related to carcinogenesis in the oral cavity.

View Figures

View References

1	Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Barterk J and Sidransky D: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56:3630–3633. 1996.PubMed/NCBI
2	Gonzalez MV, Pello MF, Lopez-Larrea C, Suarez C, Menendez MJ and Coto E: Deletion and methylation of the tumor suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol. 50:509–512. 1997. View Article : Google Scholar : PubMed/NCBI
3	El-Naggar AK, Lai S, Clayman G, Lee J-KJ, Luna MA, Goepfert H and Batsakis JG: Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous cell carcinoma. Am J Pathol. 151:1767–1774. 1997.PubMed/NCBI
4	Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG and Sidransky D: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60:892–895. 2000.PubMed/NCBI
5	Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M and Kelsey KT: Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene. 21:4231–4236. 2002. View Article : Google Scholar : PubMed/NCBI
6	Weber A, Wittekind C and Tannapfel A: Genetic and epigenetic alterations of 9p21 gene products in benign and malignant tumors of the head and neck. Pathol Res Pract. 199:391–397. 2003. View Article : Google Scholar : PubMed/NCBI
7	Ai L, Stephenson KK, Ling W, Zuo C, Mukunyadzi P, Suen JY, Hanna E and Fan C-Y: The p16 (CDKN2a/INK4a) tumor- suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. Mod Pathol. 16:944–950. 2003. View Article : Google Scholar : PubMed/NCBI
8	Maruya S, Issa J-PJ, Weber RS, Rosenthal DI, Haviland JC, Lotan R and El-Naggar AK: Differential methylation status of tumor-associated genes in head and neck squamous cell carcinoma: incidence and potential implications. Clin Cancer Res. 10:3825–3830. 2004. View Article : Google Scholar : PubMed/NCBI
9	Puri SK, Si L, Fan C-Y and Hanna E: Aberrant promoter hypermethylation of multiple genes in head and neck squamous cell carcinoma. Am J Otolaryngol. 26:12–17. 2005. View Article : Google Scholar : PubMed/NCBI
10	Shiga K, Matsuura K, Tateda M, Saijo S, Ogawa T, Miyagi T and Kobayashi T: Allelic loss correlated with tissue specificity in head and neck squamous cell carcinomas and the clinical features of patients. Tohoku J Exp Med. 204:163–172. 2004. View Article : Google Scholar : PubMed/NCBI
11	Shiga K, Yamamoto H and Okamoto H: Isolation and characterization of the human homologue of rig and its pseudogenes: The functional gene has features characteristic of housekeeping genes. Proc Natl Acad Sci USA. 87:3594–3598. 1990.PubMed/NCBI
12	Shiga K, Shiga C, Sasano H, Miyazaki S, Yamamoto T, Yamamoto M, Hayashi N, Nishihira T and Mori S: Expression of c-erbB-2 in human esophageal carcinoma cells: overexpression correlated with gene amplification or with GATA-3 transcription factor expression. Anticancer Res. 13:1293–1302. 1993.PubMed/NCBI
13	Van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W and Sidransky D: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res. 54:1156–1158. 1994.PubMed/NCBI
14	Zhang S-Y, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA and Goodrow TL: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res. 54:5050–5053. 1994.PubMed/NCBI
15	Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM and Sidransky D: Allotype of head and neck squamous cell carcinoma. Cancer Res. 54:1152–1155. 1994.PubMed/NCBI
16	Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI
17	Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D and Depinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell. 85:27–37. 1996. View Article : Google Scholar : PubMed/NCBI
18	Kamb A, Gruis NA, Weaver-Fejdhaus J, Lin Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE and Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:436–440. 1994. View Article : Google Scholar : PubMed/NCBI
19	Sherr CJ: Cancer cell cycles. Science. 274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
20	Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, et al: Frequency of homozygous deletion at p16/CDK2 in primary human tumors. Nat Genet. 11:210–212. 1995. View Article : Google Scholar : PubMed/NCBI
21	Lydiatt WM, Murty VV, Davidson BJ, Xu L, Dyomina K, Sacks PG, Schantz SP and Chaganti RS: Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors. Genes Chromosomes Cancer. 13:94–98. 1995. View Article : Google Scholar : PubMed/NCBI
22	Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-PJ, Davidson NE, Sidransky D and Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:4525–4530. 1995.PubMed/NCBI
23	Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1:686–692. 1995.